Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.
Status:
Unknown status
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
This study aims to determine if the addition of Sodium Benzoate and / or NAC to TAU will be
acceptable and tolerable and result in overall improvement of symptoms, social and cognitive
functioning in patients with early schizophrenia spectrum disorder.